Published in Lancet on April 04, 2013
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets | NCT04550455
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology (2014) 1.40
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol (2013) 1.13
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol (2015) 1.11
Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol (2013) 1.04
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.96
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol (2014) 0.95
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol (2016) 0.94
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm (2015) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A (2016) 0.92
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord (2015) 0.91
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2014) 0.89
Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol (2016) 0.86
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology (2014) 0.86
Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol (2013) 0.84
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology (2016) 0.83
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. Clin Pharmacol (2016) 0.83
Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem (2014) 0.82
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS? PLoS One (2015) 0.82
Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Front Neurol (2015) 0.82
Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci (2013) 0.81
Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity (2015) 0.81
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol (2016) 0.80
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. Mult Scler (2014) 0.80
Stage-specific immune dysregulation in multiple sclerosis. J Interferon Cytokine Res (2014) 0.79
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.79
Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis. Mediators Inflamm (2015) 0.78
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs (2014) 0.77
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77
Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis. Immunology (2016) 0.77
Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet (2016) 0.77
Population PK-PD analyses of CD25 occupancy, CD56(bright) NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol (2016) 0.76
Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST). Neuroimage Clin (2014) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
Multiple sclerosis: Daclizumab HYP shows efficacy in patients with relapsing-remitting MS. Nat Rev Neurol (2013) 0.75
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Unexpected phenotype of mice lacking Shcbp1, a protein induced during T cell proliferation. PLoS One (2014) 0.75
Anti-interleukin-2 receptor alpha for multiple sclerosis? Lancet (2013) 0.75
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther (2013) 0.75
Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clin Exp Immunol (2014) 0.75
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther (2016) 0.75
Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. Br J Pharmacol (2017) 0.75
Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. Oncotarget (2016) 0.75
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study. Neurotherapeutics (2016) 0.75
Daclizumab. Hosp Pharm (2016) 0.75
Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study. Int J MS Care (2017) 0.75
Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. CNS Drugs (2017) 0.75
Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory. Mult Scler J Exp Transl Clin (2016) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol (2010) 3.05
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol (2009) 2.95
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2003) 2.35
Head computed tomography findings predict short-term stroke risk after transient ischemic attack. Stroke (2003) 2.28
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin (2013) 2.18
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler (2005) 2.10
Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol (2014) 2.09
Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol (2010) 2.08
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
[Stem cell-based treatment of neurologic diseases]. Med Clin (Barc) (2012) 1.98
Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol (2005) 1.76
Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol (2008) 1.75
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler (2012) 1.71
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain (2010) 1.71
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord (2003) 1.65
Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol (2006) 1.64
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol (2004) 1.59
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol (2005) 1.50
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology (2013) 1.47
Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol (2005) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Res (2012) 1.45
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2012) 1.45
Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Med (2012) 1.44
Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res (2008) 1.43
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol (2008) 1.43
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol (2009) 1.41
Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies. Cogn Behav Neurol (2007) 1.39
HERVs: have we been here before? Mult Scler (2012) 1.39
CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No. Mult Scler (2013) 1.38
Arterialization of cerebral veins on dynamic MDCT angiography: a possible sign of a dural arteriovenous fistula. AJR Am J Roentgenol (2005) 1.37
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One (2010) 1.36
Stiff person syndrome. Pract Neurol (2011) 1.36
Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol (2009) 1.36
The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry (2012) 1.34